Acceleron Pharma (XLRN) Tops Q1 EPS by 4c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Tops Q1 EPS by 4c, Revenues Miss

Acceleron Reports First Quarter 2021 Financial Results

May 6, 2021 4:01 PM EDT

- PULSAR Phase 2 trial results published in New England Journal of Medicine -

- Updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept in patients with pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society (ATS) 2021 International Conference on May 19, 2021 -

- Acceleron recognized approximately $22.4 million in royalty revenue for Q1 2021 from approximately $112 million in net sales of REBLOZYL® (luspatercept-aamt) -

- REBLOZYL, the first and only erythroid maturation agent, was approved by Health Canada for the treatment of... More